CUG252

DRUG2 trials

Sponsors

Cugene Inc.

Conditions

AutoimmuneSLE (Systemic Lupus)Systemic Lupus Erythematosus

Phase 1

A Phase Ia Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered CUG252 in Normal Healthy Volunteers

CompletedNCT05328557

Cugene Inc.Systemic Lupus Erythematosus

Start: 2021-11-09End: 2022-08-03Updated: 2025-02-20

A Study in Participants With Mild-to-moderate Systemic Lupus Erythematosus

CompletedNCT05866861

Cugene Inc.Autoimmune, SLE (Systemic Lupus), Systemic Lupus Erythematosus

Start: 2023-04-24End: 2025-04-01Updated: 2026-06-24